Literature DB >> 6282372

Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat.

D Bradshaw, P H Franz, A L Sugden.   

Abstract

1 The effect of the angiotensin converting enzyme inhibitor, MK 421 (N-((S)-1-(ethoxycarbonyl)-3-phenylpropyl)L-Ala-L-Pro), on the blood pressure of two-kidney Goldblatt hypertensive rats has been investigated in relation to he initial plasma renin activity (PRA) and the initial blood pressure of the individual animals. 2 Blood pressure was monitored by an indirect tail-cuff method at 1, 3, 6 and 24 h after dosing. MK 421 produced a fall in blood pressure in the majority of animals, but the extent of this reduction varied considerably between individuals. 3 The change in blood pressure showed a significant correlation with both the initial PRA and the initial blood pressures of the animals. However, only a modest correlation was found between the initial PRA and the degree of hypertension. 4 MK 421 (10 mg/kg, orally) produced a mean blood pressure change which was statistically significant (P less than 0.001) at all times tested. 5 It is concluded that the degree of antihypertensive activity of MK 421 is related to the degree of activity of the renin-angiotensin system which, in this model at least, is reflected by the PRA.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282372      PMCID: PMC2068745          DOI: 10.1111/j.1476-5381.1982.tb09202.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Antihypertensive effect of prolonged blockade of angiotensin formation in benign and malignant, one- and two-kidney Goldblatt hypertensive rats.

Authors:  R G Bengis; T G Coleman
Journal:  Clin Sci (Lond)       Date:  1979-07       Impact factor: 6.124

2.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

3.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

4.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

Review 5.  Arterial wall or plasma renin in hypertension?

Authors:  J D Swales
Journal:  Clin Sci (Lond)       Date:  1979-04       Impact factor: 6.124

6.  Measurement of blood pressure in unanaesthetized rats and mice.

Authors:  M Gerold; H Tschirky
Journal:  Arzneimittelforschung       Date:  1968-10

7.  Converting enzyme inhibition with an orally active compound in hypertensive man.

Authors:  E L Bravo; R C Tarazi
Journal:  Hypertension       Date:  1979 Jan-Feb       Impact factor: 10.190

8.  Effect of the angiotensin II blocker 1-Sar-8-Ala-angiotensin II on renal artery clip hypertension in the rat.

Authors:  G J Macdonald; G W Boyd; W S Peart
Journal:  Circ Res       Date:  1975-11       Impact factor: 17.367

9.  Pathogenesis of malignant hypertension: experimental evidence from the renal hypertensive rat.

Authors:  J Möhring
Journal:  Clin Nephrol       Date:  1975-11       Impact factor: 0.975

10.  Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.

Authors:  G A MacGregor; N D Markandu; J E Roulston; J C Jones
Journal:  Br Med J       Date:  1979-11-03
View more
  1 in total

Review 1.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.